Todd D Gould

List of Publications by Year in Descending Order

97 papers	11,534 citations	43 h-index	106 g-index
106 ext. papers	13,192 ext. citations	7.9 avg, IF	6.57 L-index

#	Paper	IF	Citations
97	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (26)- and (5)-Methyl-(26)-hydroxynorketamines.. *ACS Chemical Neuroscience*, **2022**,	5.7	1
96	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.. *Translational Psychiatry*, **2022**, 12, 179	8.6	1
95	(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity. *Neuropharmacology*, **2022**, 214, 109153	5.5	0
94	(R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency. *Translational Psychiatry*, **2021**, 11, 583	8.6	2
93	Mechanisms of Ketamine and its Metabolites as Antidepressants.. *Biochemical Pharmacology*, **2021**, 114892	6.1	7
92	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. *Pharmacological Reviews*, **2021**, 73, 763-791	22.5	17
91	Ketamine and the Future of Rapid-Acting Antidepressants. *Annual Review of Clinical Psychology*, **2021**, 17, 207-231	20.5	8
90	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. *Journal of Affective Disorders*, **2021**, 280, 136-139	6.6	8
89	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. *Neurotoxicology and Teratology*, **2021**, 87, 106993	3.9	4
88	Sex-dependent metabolism of ketamine and ()-hydroxynorketamine in mice and humans.. *Journal of Psychopharmacology*, **2021**, 2698811211064922	4.6	0
87	Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma. *Pharmacology Biochemistry and Behavior*, **2020**, 196, 172973	3.9	7
86	Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. *Radiotherapy and Oncology*, **2020**, 146, 126-135	5.3	8
85	Antidepressant Effects and Mechanisms of Group II mGlu Receptor-Specific Negative Allosteric Modulators. *Neuron*, **2020**, 105, 1-3	13.9	4
84	Classical conditioning of antidepressant placebo effects in mice. *Psychopharmacology*, **2020**, 237, 93-102	4.7	5
83	(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. *Neuropsychopharmacology*, **2020**, 45, 426-436	8.7	25
82	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. *International Journal of Neuropsychopharmacology*, **2020**, 23, 417-425	5.8	20
81	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. *Neuropsychopharmacology*, **2020**, 45, 1398-1404	8.7	20

80	Alpha2B-Adrenergic Receptor Overexpression in the Brain Potentiate Air Pollution-induced Behavior and Blood Pressure Changes. *Toxicological Sciences*, **2019**, 169, 95-107	4.4	13
79	Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation. *Frontiers in Psychiatry*, **2019**, 10, 81	5	11
78	()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 6441-6450	11.5	73
77	Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. *Neuropsychopharmacology*, **2019**, 44, 1788-1796	8.7	29
76	(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. *British Journal of Pharmacology*, **2019**, 176, 2573-2592	8.6	38
75	Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 5160-5169	11.5	77
74	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ()-hydroxynorketamine. *Journal of Psychopharmacology*, **2019**, 33, 12-24	4.6	21
73	Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. *Annual Review of Pharmacology and Toxicology*, **2019**, 59, 213-236	17.9	59
72	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. *Molecular Psychiatry*, **2019**, 24, 1040-1052	15.1	123
71	Convergent Mechanisms Underlying Rapid Antidepressant Action. *CNS Drugs*, **2018**, 32, 197-227	6.7	92
70	Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats. *Journal of NeuroVirology*, **2018**, 24, 246-253	3.9	10
69	F102. Human Experimenter Sex Modulates Mouse Behavioral Responses to Stress and to the Antidepressant Ketamine. *Biological Psychiatry*, **2018**, 83, S277	7.9	6
68	Isoflurane but Not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?. *International Journal of Neuropsychopharmacology*, **2018**, 21, 777-785	5.8	13
67	7B2 chaperone knockout in APP model mice results in reduced plaque burden. *Scientific Reports*, **2018**, 8, 9813	4.9	1
66	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. *Psychopharmacology*, **2018**, 235, 3017-3030	4.7	53
65	Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions. *Biological Psychiatry*, **2018**, 83, 2-4	7.9	27
64	Dopamine and Stress System Modulation of Sex Differences in Decision Making. *Neuropsychopharmacology*, **2018**, 43, 313-324	8.7	35
63	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. *Pharmacological Reviews*, **2018**, 70, 621-660	22.5	395

62	Reduced levels of Cacna1c attenuate mesolimbic dopamine system function. *Genes, Brain and Behavior*, **2017**, 16, 495-505	3.6	22
61	Ketamine Mechanism of Action: Separating the Wheat from the Chaff. *Neuropsychopharmacology*, **2017**, 42, 368-369	8.7	11
60	Zanos et al. reply. *Nature*, **2017**, 546, E4-E5	50.4	21
59	Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. *Organic Letters*, **2017**, 19, 4572-4575	6.2	38
58	Decreased Nucleus Accumbens Expression of Psychiatric Disorder Risk Gene Cacna1c Promotes Susceptibility to Social Stress. *International Journal of Neuropsychopharmacology*, **2017**, 20, 428-433	5.8	22
57	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. *Biological Psychiatry*, **2017**, 81, e69-e71	7.9	20
56	A Negative Allosteric Modulator for Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. *ENeuro*, **2017**, 4,	3.9	61
55	Irving I. Gottesman (1930-2016): the multifactorial threshold model of complex phenotypes mediated by endophenotype strategies. *Genes, Brain and Behavior*, **2016**, 15, 775-776	3.6	2
54	Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7580-E7589	11.5	65
53	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature*, **2016**, 533, 481-6	50.4	903
52	Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens. *Journal of Neurochemistry*, **2016**, 139, 576-585	6	11
51	Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 359, 159-70	4.7	61
50	The prodrug DHED selectively delivers 17 estradiol to the brain for treating estrogen-responsive disorders. *Science Translational Medicine*, **2015**, 7, 297ra113	17.5	31
49	Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus. *Psychopharmacology*, **2015**, 232, 1441-50	4.7	8
48	Effects of environmental stress following myocardial infarction on behavioral measures and heart failure progression: The influence of isolated and group housing conditions. *Physiology and Behavior*, **2015**, 152, 168-74	3.5	1
47	The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 355, 76-85	4.7	77
46	Sex-dependent modulation of age-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav 1.2). *European Journal of Neuroscience*, **2015**, 42, 2499-507	3.5	17
45	Immune status influences fear and anxiety responses in mice after acute stress exposure. *Brain, Behavior, and Immunity*, **2014**, 38, 192-201	16.6	22

44	Molecular actions and clinical pharmacogenetics of lithium therapy. *Pharmacology Biochemistry and Behavior*, **2014**, 123, 3-16	3.9	76
43	Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntingtons disease. *PLoS ONE*, **2014**, 9, e87513	3.7	31
42	Differential antidepressant-like response to lithium treatment between mouse strains: effects of sex, maternal care, and mixed genetic background. *Psychopharmacology*, **2013**, 228, 411-8	4.7	12
41	Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice. *Neuropsychopharmacology*, **2013**, 38, 1937-44	8.7	26
40	Affect-related behaviors in mice selectively bred for high and low voluntary alcohol consumption. *Behavior Genetics*, **2012**, 42, 313-22	3.2	13
39	Avances en enfoques multidisciplinarios y en diversas especies para el examen de la neurobiologí de los trastornos psiquiátricos. *Psiquiatria Biologica*, **2012**, 19, 9-20	0.2	0
38	CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. *Progress in Neurobiology*, **2012**, 99, 1-14	10.9	179
37	The mouse forced swim test. *Journal of Visualized Experiments*, **2012**, e3638	1.6	188
36	Differential lithium efficacy in reducing suicidal behaviors compared with suicidal thoughts. *American Journal of Psychiatry*, **2012**, 169, 98-9; author reply 99	11.9	2
35	Advances in multidisciplinary and cross-species approaches to examine the neurobiology of psychiatric disorders. *European Neuropsychopharmacology*, **2011**, 21, 532-44	1.2	29
34	Antidepressant-like responses to lithium in genetically diverse mouse strains. *Genes, Brain and Behavior*, **2011**, 10, 434-43	3.6	50
33	Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. *Biological Psychiatry*, **2010**, 68, 801-10	7.9	131
32	Shock-induced aggression in mice is modified by lithium. *Pharmacology Biochemistry and Behavior*, **2010**, 94, 380-6	3.9	29
31	Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. *Brain, Behavior, and Immunity*, **2009**, 23, 784-93	16.6	79
30	Lithiums antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. *Annual Review of Pharmacology and Toxicology*, **2009**, 49, 175-98	17.9	75
29	Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. *Neuropharmacology*, **2008**, 54, 577-87	5.5	92
28	Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. *Behavioural Brain Research*, **2008**, 189, 117-25	3.4	62
27	Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. *Neuroscience and Biobehavioral Reviews*, **2007**, 31, 825-31	9	99

26	The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. *Neuroscience and Biobehavioral Reviews*, **2007**, 31, 932-62	9	102
25	Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. *Neuropsychopharmacology*, **2007**, 32, 1321-33	8.7	101
24	Performance on a virtual reality spatial memory navigation task in depressed patients. *American Journal of Psychiatry*, **2007**, 164, 516-9	11.9	82
23	Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. *Neuropsychopharmacology*, **2007**, 32, 2173-83	8.7	121
22	Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders. *Current Signal Transduction Therapy*, **2007**, 2, 101-110	0.8	2
21	Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. *Expert Opinion on Therapeutic Targets*, **2006**, 10, 377-92	6.4	29
20	Toward constructing an endophenotype strategy for bipolar disorders. *Biological Psychiatry*, **2006**, 60, 93-105	7.9	344
19	Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. *Current Drug Targets*, **2006**, 7, 1399-409	3	106
18	Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. *Neuropsychopharmacology*, **2005**, 30, 1223-37	8.7	303
17	Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. *Molecular Neurobiology*, **2005**, 32, 173-202	6.2	123
16	DARPP-32: A molecular switch at the nexus of reward pathway plasticity. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 253-4	11.5	42
15	Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. *Journal of Neuroscience*, **2004**, 24, 6590-9	6.6	345
14	In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. *Neuropsychopharmacology*, **2004**, 29, 32-8	8.7	183
13	Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications. *Clinical Neuroscience Research*, **2004**, 4, 137-153		8
12	GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology and treatment of mood disorders?. *Drug Discovery Today Disease Mechanisms*, **2004**, 1, 419-428		7
11	AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. *International Journal of Neuropsychopharmacology*, **2004**, 7, 387-90	5.8	253
10	Molecular effects of lithium. *Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics*, **2004**, 4, 259-72		159
9	Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. *Journal of Clinical Psychiatry*, **2004**, 65, 10-21	4.6	146

8	The endophenotype concept in psychiatry: etymology and strategic intentions. *American Journal of Psychiatry*, **2003**, 160, 636-45	11.9	4393
7	Post-mortem interval effects on the phosphorylation of signaling proteins. *Neuropsychopharmacology*, **2003**, 28, 1017-25	8.7	74
6	The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. *Journal of Neuroscience*, **2003**, 23, 7311-6	6.6	414
5	Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. *Pharmacological Research*, **2003**, 48, 49-53	10.2	44
4	Mood stabilizer psychopharmacology. *Clinical Neuroscience Research*, **2002**, 2, 193-212		47
3	The Wnt signaling pathway in bipolar disorder. *Neuroscientist*, **2002**, 8, 497-511	7.6	133
2	Signaling networks in the pathophysiology and treatment of mood disorders. *Journal of Psychosomatic Research*, **2002**, 53, 687-97	4.1	101
1	Altered performance on an ocular fixation task in attention-deficit/hyperactivity disorder. *Biological Psychiatry*, **2001**, 50, 633-5	7.9	55